drugset / Trial / NCT00058487

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

NCT00058487 ↗

Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of hepatocellular (liver) cancer by stopping blood flow to the tumor. Combining epirubicin with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with thalidomide in treating patients who have unresectable or metastatic liver cancer.

Timeline

Start
2001-12
Primary completion
—
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule 20 mg/m2 Intravenous
Subject Thalidomide Other / unclassified 200 mg Oral

Indications